In addition to established platform technologies, GSK is building new platforms such as the Multiple Antigen-Presenting System (MAPS) and mRNA, key to addressing the most complex diseases.

As one of the leading vaccine developers, GSK is keen to facilitate the exchange of intellectual know-how between the 2,000 scientists at its R&D sites in Rixensart (Belgium), Rockville (Maryland ...